# Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A

> **NCT00221039** · PHASE4 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 7 (actual)

## Conditions studied

- Cutaneous T Cell Lymphoma
- Mycosis Fungoides

## Interventions

- **DRUG:** Methoxsalen+ECP

## Key facts

- **NCT ID:** NCT00221039
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04-02
- **Primary completion:** 2011-04-05
- **Final completion:** 2011-04-05
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2018-08-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00221039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00221039, "Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A". Retrieved via AI Analytics 2026-09-28 from https://api.ai-analytics.org/clinical/NCT00221039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*